Earnings GuidanceAbbVie raises its 2024 revenue guidance to $56 billion, driven by strong performance in Skyrizi and Rinvoq.
Immunology And Inflammation GrowthContinued strong uptake of Skyrizi and Rinvoq in treating psoriatic disease and inflammatory bowel disease highlights significant growth potential beyond Humira.
Oncology And Neuroscience PerformanceSolid quarterly results in oncology and neuroscience portfolios contribute to AbbVie's robust growth, with Imbruvica sales maintaining strength.